A large-scale trial has found a that pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of symptoms compared to placebo in people with dementia, a condition for which no treatments are currently licensed.
from Medindia Health News https://ift.tt/3gcQUf7
No comments:
Post a Comment